HER2-Positive Breast Carcinoma — Trials

HER2-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 140
Recruiting: 73
Ph III recruiting: 15
Growth YoY: +11.5%
Industry share: 19%
Top sponsor: Fudan University
Termination share: 43.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–50 of 377 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05132582	A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer(HER2CLIMB-05)	active not recruiting	Phase 3	654	Seagen, a wholly owned subsidiary of PfizerINDUSTRY	23	Sep 29, 2026	clinicaltrials
NCT05880160	Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction(HER-SAFE)	completed	N/A	90	University College, LondonOTHER